《新股》藥捷安康通過上市聆訊 去年虧損2.75億人幣
藥捷安康通過港交所(00388.HK)上市聆訊,將在上市。公司核心業務模式涉及自主開發、研究及商業化小分子藥物,以解決腫瘤、炎症及心臟代謝疾病領域的大量醫療需求。
招股書披露,公司是以臨牀需求爲導向、處於註冊臨牀階段的生物製藥公司,專注於發現及開發腫瘤、炎症及心臟代謝疾病小分子創新療法。自於2014年註冊成立以來,已自主發現及開發一種核心產品Tinengotinib(TT00420)以及建立五種臨牀階段候選產品及一種臨牀前階段候選產品的管線。
核心產品Tinengotinib是一種獨特的多靶點激(酉每)(MTK)抑制劑,主要靶向三個關鍵通路(即FGFR/VEGFR、JAK和Aurora激(酉每))。
公司全球合作夥伴覆蓋領先的製藥公司,包括LG Chem、羅氏、帝人及EA Pharma,合作夥伴關係覆蓋各項業務合作模式,包括臨牀合作、聯合研發及授權引進。
資料顯示,藥捷安康2023年收入118.1萬元人民幣(下同),而2024年無錄得營收;研發成本分別爲3.45億及2.44億元;期內分別虧損3.43億及2.75億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.